BIOPHARMA
ByPfizer Repositions for Sustainable Growth in 2025 as Core Therapeutic Franchises Reassert Leadership
Pfizer Inc. reported full-year 2025 revenues of $62.6 billion, marking a pivotal year in the company’s post-pandemic transformation.…
Eli Lilly Delivers Transformational Growth in 2025, Anchored by Metabolic Leadership and Innovation Execution
Indianapolis, IN – February 2026 – Eli Lilly and Company reported exceptional full-year financial and operational performance in…
Merck Reinforces Oncology Leadership and Therapeutic Area Depth with Robust 2025 Performance
Rahway, NJ – February 2026 – Merck & Co., Inc. reported strong full-year 2025 financial and operational performance,…
AbbVie Accelerates Portfolio-Led Growth in 2025 and Strengthens Its Long-Term Therapeutic Leadership
North Chicago, IL – February 2026 – AbbVie Inc. reported a strong full-year financial performance in 2025, underscoring…
VA’s Nationwide Ambient AI Scribe Rollout: Burnout Buster or Documentation Digitized Trap?
The U.S. Department of Veterans Affairs on March 4, 2026, greenlit ambient scribe AI from Knowtex and Abridge…
Gilead’s $8B Arcellx CAR-T Swoop & Lilly Zepbound Triumph: Obesity/CAR-T Mania or Bubble Burst Ahead?
Gilead’s March 2026 $8B acquisition of Arcellx—securing CAR-T anito-cel for multiple myeloma with 73% ORR Phase 1b data—and…
